Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2026
Fresenius Kabi recalls Tyenne arthritis injection lot over glass particles
Fresenius Kabi initiated a nationwide recall of one lot of Tyenne (tocilizumab-aazg) Injection 400 mg/20 mL vials after an internal investigation found glass particles in the product, which the company warned could cause local irritation, vein inflammation, blood vessel blockage and clotting, pulmonary embolism, permanent organ damage or death. The recall, announced by the FDA on Aug. 11, covers lot 16UI07 (NDC 65219-594-20), shipped between March 3 and 25, 2026, with an August 2028 expiration date, and sold to wholesalers, distributors and customers across the United States.
2024
Cellular Origins and Fresenius Kabi sign development agreement
Cellular Origins and Fresenius Kabi signed a development agreement to work on digitally and physically integrating Fresenius Kabi’s cell therapy technologies into Cellular Origins’ Constellation manufacturing platform. Initial integration work focuses on the Cue Cell Processing System.
2020
QuVa Pharma recalls R.E.C.K. product lots
QuVa Pharma announced a voluntary recall of all lots of its R.E.C.K. 50 ml product prepared using ketorolac recalled by Fresenius Kabi. QuVa said it contacted affected hospital pharmacy customers and asked them to quarantine remaining product, report unused quantities, and return finished goods for destruction. The source says the ketorolac recall was due to particulate matter found in reserve sample vials.